Everything below concerns mass spectrometry. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Bigga (Jamaica) Tropical Crema Soda (El Salvador) DG Soft Drink Cream Soda (Jamaica) Colombiana (Colombia) Kola Román (Colombia) Frescolita (Venezuela) – a bubble gum-flavored soda Kola Dumbo (Venezuela) – a bubble gum-flavored soda Grapette (Venezuela) – a bubble gum-flavored soda Marbel (Venezuela) – a bubble gum-flavored soda Inca Kola (Peru) – sometimes considered a champagne cola, sometimes considered its own drink Old Jamaica Cream Soda (Jamaica) Solo Beverage Company (Trinidad) ToniCol (Mexico) – a naturally flavored vanilla soda
=== Additives === Compounds can be added in both organic and conventional hydroponic systems to improve nutrition acquisition and uptake by the plant. Chelating agents and humic acid have been shown to increase nutrient uptake. Additionally, plant growth promoting rhizobacteria (PGPR), which are regularly utilized in field and greenhouse agriculture, have been shown to benefit hydroponic plant growth development and nutrient acquisition. Some PGPR are known to increase nitrogen fixation. While nitrogen is generally abundant in hydroponic systems with properly maintained fertilizer regimens, Azospirillum and Azotobacter genera can help maintain mobilized forms of nitrogen in systems with higher microbial growth in the rhizosphere. Traditional fertilizer methods often lead to high accumulated concentrations of nitrate within plant tissue at harvest. Rhodopseudo-monas palustris has been shown to increase nitrogen use efficiency, increase yield, and decrease nitrate concentration by 88% at harvest compared to traditional hydroponic fertilizer methods in leafy greens. Many Bacillus spp., Pseudomonas spp. and Streptomyces spp. convert forms of phosphorus in the soil that are unavailable to the plant into soluble anions by decreasing soil pH, releasing phosphorus bound in chelated form that is available in a wider pH range, and mineralizing organic phosphorus. Some studies have found that Bacillus inoculants allow hydroponic leaf lettuce to overcome high salt stress that would otherwise reduce growth.
David Baker online talk: "Crowd Sourcing Protein Folding: Rosetta@Home and FoldIt" Archived July 2, 2017, at the Wayback Machine David Baker online seminar: "Introduction to Protein Design" Archived April 1, 2016, at the Wayback Machine David Baker online seminar: "Design of New Protein Functions" Archived April 1, 2016, at the Wayback Machine
==== MeSH D12.776.422.512.426 – hemoglobins, abnormal ==== MeSH D12.776.422.512.426.338 – hemoglobin C MeSH D12.776.422.512.426.375 – hemoglobin E MeSH D12.776.422.512.426.463 – hemoglobin H MeSH D12.776.422.512.426.480 – hemoglobin J MeSH D12.776.422.512.426.510 – hemoglobin M MeSH D12.776.422.512.426.588 – hemoglobin, sickle
== History == Flutamide was first synthesized in 1967 by Neri and colleagues at Schering Plough Corporation. It was originally synthesized as a bacteriostatic agent, but was subsequently, and serendipitously found to possess antiandrogen activity. The code name of flutamide during development was SCH-13521. Clinical research of the medication began in 1971, and it was first marketed in 1983, specifically in Chile under the brand name Drogenil and in West Germany under the brand name Flugerel. Flutamide was not introduced in the United States until 1989; it was specifically approved by the U.S. Food and Drug Administration for the treatment of metastatic prostate cancer in combination with a gonadotropin-releasing hormone (GnRH) analogue. The medication was first studied for the treatment of hirsutism in women in 1989. It was the first "pure antiandrogen" to be studied in the treatment of hirsutism. Flutamide was the first NSAA to be introduced, and was followed by nilutamide in 1989 and then bicalutamide in 1995.
Sources: en.wikipedia.org
The substrate of this enzyme is geranylgeranyl pyrophosphate, which reacts with three equivalents of reduced nicotinamide adenine dinucleotide phosphate (NADPH), and three protons. The product is phytyl diphosphate and oxidised NADP+. It can also act on geranylgeranyl-chlorophyll a.
Total production from fishing in North and Baltic Seas was 40 780 tonnes in 2019, ca. 1/3 German production. In the Baltic Sea total production amounted to 10377 tonnes (2019), of which 5432 tonnes of sprat, 2568 tonnes of flatfish and 1190 tonnes of cod. In the North Sea the numbers were 19,487 tonnes of mussels, 3560 tonnes of North Sea shrimp, 1166 tonnes of herring and 7062 other fishes. One important aquaculture product is mussels, 16864 tonnes. Inland fishing and aquaculture are not significant, with 221 and 250 tonnes in 2019, respectively.
The primary use for indigo is as a dye for cotton yarn, mainly used in the production of denim cloth suitable for blue jeans; on average, a pair of blue jeans requires 3–12 grams (0.11–0.42 oz) of dye. Smaller quantities are used in the dyeing of wool and silk. Indigo's widespread use was partly due to its colorfast properties, as it binds effectively to fibers while allowing repeated dyeing processes that produce a range of shades. Indigo carmine, also known as indigo, is an indigo derivative which is also used as a colorant. About 20,000 tonnes are produced annually, again mainly for the production of blue jeans. Indigo is also used to dye the skin in Egypt, Kurdistan, and West Africa.
=== Horse racing === In June 2015, Monster agreed to a sponsorship deal with Zayat Stables to sponsor the race horse American Pharoah, rumored to be the largest single-horse advertising sponsorship to-date. The deal allows the product's logo to be used on the horse sheets, on jockey Victor Espinoza's shirt and boots, as well as caps and other gear worn by people around the horse.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.